+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Opioid dipeptide derivatives with a mixed mu agonist/delta antagonist, partial mu agonist/delta antagonist or mu agonist/partial delta agonist profile



Opioid dipeptide derivatives with a mixed mu agonist/delta antagonist, partial mu agonist/delta antagonist or mu agonist/partial delta agonist profile



Fields, Gregg B [Author], Tam, James P [Author], Barany, George [Author] Peptides for the new millennium 229-230




(PDF emailed within 1 workday: $29.90)

Accession: 035430654

Download citation: RISBibTeXText



Related references

Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands. Journal of Medicinal Chemistry 50(12): 2753-2766, 2007

Novel deltorphin heptapeptide analogs with potent delta agonist, delta antagonist, or mixed mu antagonist/delta agonist properties. Journal Of Medicinal Chemistry. 38(20): 3995-3999, 1995

Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. Journal of Medicinal Chemistry 52(23): 7724-7731, 2010

Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. Journal of Pharmacology and Experimental Therapeutics 301(2): 661-671, 2002

Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties. Journal of Medicinal Chemistry 47(14): 3591-3599, 2004

Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. Journal of Pharmacology and Experimental Therapeutics 298(3): 1015-1020, 2001

Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist. Journal of Pharmacology and Experimental Therapeutics 284(1): 283-290, 1998

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Organic and Biomolecular Chemistry 5(8): 1177-1190, 2007

Effects of dopamine antagonist and kappa-selective opioid agonist on the delta-selective opioid agonist enkephalin-induced behavioral alterations in mice. Japanese Journal of Pharmacology 64(SUPPL 1): 179P, 1994

Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. Journal of Medicinal Chemistry 45(3): 713-720, 2002

Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding. British Journal of Pharmacology 116(7): 2931-2938, 1995

Delta antagonist and kappa agonist activity of Naltriben: evidence for differential kappa interaction with the delta 1 and delta 2 opioid receptor subtypes. Life Sciences 55(4): Pl79-Pl84, 1994

Radiolabelling of the human 5-HT-2A receptor with an agonist, a partial agonist and antagonist: Effects on apparent agonist affinities. Biochemical Pharmacology 51(1): 71-76, 1996

A chimeric opioid peptide with mixed mu agonist/delta antagonist properties. Journal of Peptide Research 63(2): 63-68, 2004

Delineation of mu-antagonist, partial kappa agonist and non-opioid agonist activity of cyclazocine using urinary output of rats. Pharmacology, Biochemistry, and Behavior 26(4): 705-707, 1987